China National Accord Medicines Corporation Ltd.
The Third Quarterly Report for 2020
October 2020
1
Section I. Important Notice
Board of Directors, Supervisory Committee, all directors, supervisors and senior
executives of China National Accord Medicines Corporation Ltd. (hereinafter
referred to as the Company) hereby confirm that there are no any fictitious
statements, misleading statements, or important omissions carried in this report,
and shall take all responsibilities, individual and/or joint, for the reality,
accuracy and completion of the whole contents.
All directors are present the meeting of the Board for deliberating the Third
Quarter Report of the Company in person.
Lin Zhaoxiong, person in charge of the Company, head of the accounting works
Gu Guolin and Wang Ying, accounting body principals (accountant in charge)
hereby confirm that the Financial Report of the Third Quarterly Report is
authentic, accurate and complete.
2
Section II. Basic information of Company
I. Main accounting data and index
Whether it has retroactive adjustment or re-statement on previous accounting data or not
√ Yes □No
Cause of retroactive adjustment or restatement
Enterprises combined under the same control
Period-end of last year Increase/decrease
Current period-end
Before adjustment After adjustment After adjustment
Total assets (RMB) 42,013,200,732.51 33,520,609,123.67 34,028,843,214.20 23.46%
Net assets attributable to
shareholders of listed company 13,554,151,733.76 12,806,410,865.92 12,911,140,435.88 4.98%
(RMB)
Increase/d
Increase/d ecrease in
ecrease in compariso
compariso n with
Same period of last Same period of last
n with year-begin
year Year-begin year
Current same to
to end of
period period of period-end
the Period
last year of last
year
After
Before After After Before After
adjustmen
adjustment adjustment adjustment adjustment adjustment
t
15,710,564 13,647,793 13,824,236 42,880,505 38,875,940 39,423,43
Operating revenue (RMB) 13.65% 8.77%
,937.11 ,431.64 ,956.99 ,125.63 ,809.07 5,772.29
Net profit attributable to
354,134,16 311,310,70 310,253,59 997,585,74 962,144,06 959,408,0
shareholders of the listed company 14.14% 3.98%
5.83 6.52 2.48 6.42 6.92 07.03
(RMB)
Net profit attributable to
shareholders of the listed company 354,311,45 303,365,28 303,365,28 981,328,47 943,065,72 943,065,7
16.79% 4.06%
after deducting non-recurring gains 3.14 0.52 0.52 2.59 8.47 28.47
and losses (RMB)
Net cash flow arising from 545,143,14 -90,795,42 -80,360,84 1,983,347, 1,072,962, 1,058,793,
778.37% 87.32%
operating activities (RMB) 2.89 0.13 0.58 186.24 161.22 280.31
Basic earnings per share 0.83 0.74 0.72 15.28% 2.33 2.25 2.24 4.02%
3
(RMB/Share)
Diluted earnings per share
0.83 0.74 0.72 15.28% 2.33 2.25 2.24 4.02%
(RMB/Share)
0.29
0.15
percentage
Weighted average ROE 2.65% 2.53% 2.50% percentage 7.56% 7.94% 7.85%
points
points up
decline
Items and amount of extraordinary profit (gains)/losses
√Applicable □Not applicable
In RMB
Amount from year-begin to
Item Note
end of the Period
Gains/losses from the disposal of non-current asset (including the Mainly for the income from
6,670,438.32
write-off that accrued for impairment of assets) off-lease stores.
Governmental subsidy reckoned into current gains/losses (not Mainly affected by the
including the subsidy enjoyed in quota or ration according to COVID-19, all kinds of special
36,307,932.91
national standards, which are closely relevant to enterprise’s subsidies received in the period
business) and tax reduction & exemption.
Reversal of impairment reserve for account receivable with
378,494.91
separate impairment testing
Consigning fee received for consigned operation 961,488.75
Other non-operating income and expenditure except for the
-11,989,346.42
aforementioned items
Gains/losses items qualified definition of the non-recurring
955,958.26
gains/losses
Less: impact on income tax 7,360,561.86
Impact on minority shareholders’ equity (post-tax) 9,667,131.04
Total 16,257,273.83 --
Concerning the extraordinary profit (gain)/loss defined by Q&A Announcement No.1 on Information Disclosure for Companies
Offering Their Securities to the Public --- Extraordinary Profit/loss, and the items defined as recurring profit (gain)/loss according to
the lists of extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their
Securities to the Public --- Extraordinary Profit/loss, explain reasons
□ Applicable √ Not applicable
In reporting period, the Company has no particular about items defined as recurring profit (gain)/loss according to the lists of
extraordinary profit (gain)/loss in Q&A Announcement No.1 on Information Disclosure for Companies Offering Their Securities to
the Public --- Extraordinary Profit/loss.
4
II. Statement of the total shareholders and shares-held of top ten shareholders at end of the
Period
1. Total number of common shareholders at the end of this report period and top ten common shareholders
In Share
Total preference shareholders
Total common shareholders at the with voting rights recovered at
34,927 0
end of report period end of reporting period (if
applicable)
Top ten shareholders
Amount of Number of share pledged/frozen
Nature of Proportion of Amount of shares
Shareholders restricted shares
shareholder shares held held State of share Amount
held
Sinopharm Group State-owned
56.06% 239,999,991 5,505,770
Co., Ltd. corporate
FIRST SENTIER
INVESTORS
GLOBAL
UMBRELLA Overseas
2.68% 11,469,644
FUND PLC - corporate
FSSA CHINA
GROWTH
FUND
Shanghai Gaoyi
Asset
Management
Domestic non
Partnership
state-owned 2.34% 10,000,000
(Limited
corporate
Partnership)-Gao
yi Linshan No. 1
Yuanwang Fund
Hong Kong
Securities Overseas
2.15% 9,199,504
Clearing corporate
Company Ltd.
National Social Domestic non
Security Fund state-owned 1.59% 6,791,699
118 Portfolio corporate
China National
State-owned
Pharmaceutical 1.24% 5,323,043
corporate
Foreign Trade
5
Corp.
Central Huijin State-owned
0.89% 3,804,400
Investment Ltd. corporate
Industrial and
Commercial
Bank of Domestic non
China-Guangfa state-owned 0.89% 3,802,617
Steady Growth corporate
Securities
Investment Fund
BBH BOS S/A
FIDELITY FD - Overseas
0.78% 3,358,761
CHINA FOCUS corporate
FD
National Social Domestic non
Security Fund state-owned 0.78% 3,333,913
115 Portfolio corporate
Particular about top ten shareholders with un-restrict shares held
Type of shares
Shareholders Amount of un-restrict shares held
Type Amount
RMB ordinary
Sinopharm Group Co., Ltd. 234,494,221 234,494,221
shares
FIRST SENTIER INVESTORS Domestically
GLOBAL UMBRELLA FUND PLC 11,469,644 listed foreign 11,469,644
- FSSA CHINA GROWTH FUND shares
Shanghai Gaoyi Asset Management
Partnership (Limited RMB ordinary
10,000,000 10,000,000
Partnership)-Gaoyi Linshan No. 1 shares
Yuanwang Fund
Hong Kong Securities Clearing RMB ordinary
9,199,504 9,199,504
Company Ltd. shares
National Social Security Fund 118 RMB ordinary
6,791,699 6,791,699
Portfolio shares
China National Pharmaceutical RMB ordinary
5,323,043 5,323,043
Foreign Trade Corp. shares
RMB ordinary
Central Huijin Investment Ltd. 3,804,400 3,804,400
shares
Industrial and Commercial Bank of
RMB ordinary
China-Guangfa Steady Growth 3,802,617 3,802,617
shares
Securities Investment Fund
6
Domestically
BBH BOS S/A FIDELITY FD -
3,358,761 listed foreign 3,358,761
CHINA FOCUS FD
shares
National Social Security Fund 115 RMB ordinary
3,333,913 3,333,913
Portfolio shares
Sinopharm Group Co., Ltd. and China National Pharmaceutical Foreign Trade Corporation
Explanation on associated have the same actual controller, which is China National Pharmaceutical Group Corporation.
relationship among the aforesaid It is unknown that there exists no associated relationship or belongs to the consistent actionist
shareholders among the other tradable shareholders regulated by the Management Measure of Information
Disclosure on Change of Shareholding for Listed Companies.
Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreement
dealing in reporting period
□ Yes √ No
The shareholders of the Company have no buy-back agreement dealing in reporting period.
2. Total of shareholders with preferred stock held and the top ten shareholdings
□Applicable √Not applicable
7
Section III. Important events
I. Particular about major changes from items of main accounting statements and financial
indexes as well as reasons
√ Applicable □Not applicable
1. Notes receivable had a decrease of 276.5989 million yuan from the beginning of the period, with a growth rate
of -34.87%, mainly due to changes in the procurement mode of hospital customers and changes in settlement
methods caused by the GPO policy;
2. Accounts receivable had an increase of 5,446.291 million yuan from the beginning of the period, with a growth
rate of 50.84%, mainly due to the increase in days of turnover of accounts receivable caused by impact of the
COVID-19 outbreak and market environment, and also the increase in accounts receivable at the end of the period
brought about by the newly merged company;
3. Receivable financing had an increase of 168.1186 million yuan from the beginning of the period, with a growth
rate of 37.67%, mainly due to changes in settlement methods with customers and the increase in financing of
accounts receivable at the end of the period brought about by the newly merged company;
4. Advances to suppliers had an increase of 138.3328 million yuan from the beginning of the period, with a
growth rate of 35.49%, mainly due to the increase in prepayments as the import letters of credit expired;
5. Dividend receivable had a decrease of 0.8349 million yuan from the beginning of the period, with a growth rate
of -100%, mainly because Shanghai Dingqun Enterprise Management Consulting Co., Ltd. has been included in
the scope of consolidation in the current period, for the dividends receivable of the same period last year, there is
no more balance at the consolidation level after internal offset;
6. Other current assets had a decrease of 32.7243 million yuan from the beginning of the period, with a growth
rate of -32.02%, mainly due to the decrease in the input tax to be deducted for value-added tax;
7. Intangible assets had an increase of 373.8836 million yuan from the beginning of the period, with a growth rate
of 99.76%, mainly due to the sales network generated by the acquisition of Shanghai Dingqun Enterprise
Management Consulting Co., Ltd. by the subsidiary Guoda Drug Store in the current period;
8. Goodwill had an increase of 1,736.49 million yuan from the beginning of the period, with a growth rate of
171.92%, mainly due to the acquisition of Chengda Fangyuan Pharmaceutical Group Co., Ltd. and Shanghai
Dingqun Enterprise Management Consulting Co., Ltd. by the subsidiary Guoda Drug Store in the current period;
8
9. Deferred tax assets had an increase of 35.4016 million yuan from the beginning of the period, with a growth
rate of 56.09%, mainly due to the increase in the ending balance brought about by the newly merged companies in
the current period;
10. Other non-current assets had an increase of 195.5173 million yuan from the beginning of the period, with a
growth rate of 252.75%, mainly due to the procurement of emergency special reserve materials for the prevention
and control of the COVID-19 outbreak at the request of the government;
11. Short-term borrowings had an increase of 1,770.8543 million yuan from the beginning of the period, with a
growth rate of 121.87%, mainly due to the increase in supply chain financing in the current period and the
increase in the ending short-term loans brought about by the newly merged companies;
12. Accounts payable had an increase of 3,488.0446 million from the beginning of the period, with a growth rate
of 52.03%, mainly because the number of days for settlement of accounts payable has increased due to the impact
of the COVID-19 outbreak, and the ending accounts payable brought about by the newly merged companies have
increased;
13. Interest payable had a decrease of 9.5779 million yuan from the beginning of the period, with a growth rate of
-40.53%, mainly due to the scheduled payment of factoring interest on accounts receivable;
14. Long-term borrowings had an increase of 31.6338 million yuan from the beginning of the period, with a
growth rate of 100.00%, mainly due to the loan received from Sinopharm Finance Company entrusted by China
National Pharmaceutical Group Corporation in the period;
15. Long-term payable had an increase of 6.1382 million yuan from the beginning of the period, with a growth
rate of 767.27%, mainly due to the increase in the ending balance brought about by the newly merged companies
in the current period;
16. Provisions had an increase of 67.7774 million yuan from the beginning of the period, with a growth rate of
100.00%, mainly due to the increase of the ending balance caused by new enterprise incorporated in current
period;
17. Deferred tax liabilities had an increase of 90.3191 million yuan from the beginning of the period, with a
growth rate of 76.36%, mainly due to the acquisition of Shanghai Dingqun Enterprise Management Consulting
Co., Ltd. by the subsidiary Guoda Drug Store in the current period, resulting in deferred income tax liabilities
recognized by the asset fair assessment and appreciation；
18. Other non-current liabilities had an increase of 463.1607 million yuan from the beginning of the period, with a
growth rate of 632.25%, mainly due to the advance purchase of government emergency reserve materials for the
9
prevention and control of the COVID-19 outbreak;
19. Other incomes had a year-on-year increase of 17.58 million yuan, with a growth rate of 61.45%, mainly
because various special subsidies and tax reductions received in this period have increased due to the impact of
the COVID-19 outbreak;
20. Credit impairment losses had a year-on-year increase of 14.4377 million yuan, with a growth rate of 98.58%,
mainly due to the expansion of sales volume, the increase in ending accounts receivable compared with the same
period last year, and the number of days of accounts receivable turnover has increased due to the impact of the
new crown pneumonia epidemic, so the provision for bad debts has increased accordingly;
21. Impairment losses had a year-on-year increase of 4.7512 million yuan, with a growth rate of 571.45%, mainly
due to the increase in the provision for inventory depreciation in the current period;
22. Gain on disposal of assets had a year-on-year increase of 6.7387 million yuan, with a growth rate of
1,153.53%, mainly due to the loss resulting from lease cancellation incurred by the implementation of the new
lease standard for retail stores;
23. Non-operating income had a year-on-year increase of 2.8967 million yuan,with a growth rate of 42.09%,
mainly due to the transfer of accounts payable that are not required to be paid into non-operating income during
the current period;
24. Non-operating expenses had a year-on-year increase of 18.0083 million yuan, with a growth rate of 754.04%,
mainly due to the provision of litigation compensation in the current period, there was no such matter in the same
period last year;
25. Non-controlling interests had an increase of 59.1853 million yuan, with a growth rate of 36.00%, mainly due
to the acquisition of non-wholly-owned subsidiaries by the subsidiary Guoda Drug Store during the current period,
which caused an increase in the profit and loss attributable to minority shareholders and an increase in the net
profit of Guoda Drug Store on a year-on-year basis, and the minority shareholders' profit and loss attributable to
strategic investor Walgreens Boots Alliance (Hong Kong) Investments Limited (hereinafter referred to as "WBA")
increased accordingly;
26. Other comprehensive income, net of tax had a year-on-year increase of 0.1439 million yuan, with a growth
rate of 100.00%, mainly due to the change of other equity from associated enterprise in the period;
27. Total comprehensive income attributable to non-controlling interests had a year-on-year increase of 59.1853
million yuan, with a growth rate of 36.00%, mainly due to the new acquisition of non-wholly-owned subsidiaries
by the subsidiary Guoda Drug Store during the current period, which caused an increase in comprehensive income
10
attributable to minority shareholders and an increase in the net profit of Guoda Drug Store on a year-on-year basis,
and the comprehensive income of minority shareholders attributable to WBA increased correspondingly;
28. Receipts of taxes and surcharges refunds had an increase of 7.2765 million yuan year-on-year, with a growth
rate of 207.42%, mainly due to the increase in tax refunds received in this period compared with the same period
last year;
29. Other cash receipts relating to operating activities had a year-on-year increase of 698.8992 million yuan, with
a growth rate of 135.09%, mainly due to the receipt of special reserve funds for the prevention and control of the
COVID-19 outbreak, there was no such matter in the same period last year;
30. Cash payments related to other operating activities had a year-on-year increase of 259.1235 million yuan, with
a growth rate of 32.11%, mainly due to the year-on-year increase in various expenses and current accounts paid
during the current period;
31. Net cash flows from operating activities had a year-on-year increase of 924.5539 million yuan, with a growth
rate of 87.32%, mainly because the company has formulated stricter fund management plans, increased the
collection of accounts receivable and effectively controlled purchase payments, and received the emergency
special reserve funds for the prevention and control of the COVID-19 outbreak in the current period;
32. Cash receipts from returns of investments had a year-on-year increase of 19.0276 million yuan, with a growth
rate of 100.00%, because received the withdrawal of principal from the China National Zhongjin Medical Industry
Fund;
33. Cash receipts from returns on investments had a year-on-year increase of 81.3311 million yuan, with a growth
rate of 103.95%, because the cash dividends received from associates in the current period increased on a
year-on-year basis;
34. Cash receipts related to other investing activities had a year-on-year decrease of 346.5745 million yuan, with a
growth rate of -94.02%, because the consolidated subsidiary Pudong New Area of Shanghai Pharmaceutical
Medicine Co., Ltd. under the same control of the subsidiary Guoda Drug Store in the current period received the
funds allocated from the fund pool of its original parent company Sinopharm Group Co., Ltd. in the same period
of last year, and the funds originally collected was taken back into the cash pool in this period;
35. Sub-total of cash inflows from investing activities had a year-on-year decrease of 245.9187 million yuan, with
a growth rate of -54.43%, mainly because the consolidated subsidiary Pudong New Area of Shanghai
Pharmaceutical Medicine Co., Ltd. under the same control of the subsidiary Guoda Drug Store in the current
period received the funds allocated from the fund pool of its original parent company Sinopharm Group Co., Ltd.
11
in the same period of last year, and the funds originally collected was taken back into the cash pool in this period;
36. Cash paid for acquisition of investments had a year-on-year decrease of 56.1288 million yuan, with a growth
rate of -66.39%, mainly due to the decrease in the store transfer fee paid by the subsidiary Guoda Drug Store for
the purchase of retail stores during the current period;
37. Net cash paid for acquisition of subsidiaries and other business units had an a year-on-year increase of
2,379.2871 million yuan, with a growth rate of 44,656.29%, mainly due to the net cash paid for the acquisition of
Chengda Fangyuan Pharmaceutical Group Co., Ltd. and Shanghai Dingqun Enterprise Management Consulting
Co., Ltd. by the subsidiary Guoda Drug Store, there was no such matter in the same period last year;
38. Cash payments related to other investing activities had a year-on-year decrease of 340.7033 million yuan, with
a growth rate of -98.55%, mainly because the subsidiary Guoda Drug Store merged into Pudong New Area of
Shanghai Pharmaceutical Medicine Co., Ltd. under the same control during the current period, and the fund pool
in the same period last year was collected to the original parent company Sinopharm Group Co., Ltd., there was
no such matter in this period;
39. Sub-total of cash outflows from investing activities had a year-on-year increase of 2,004.8201 million yuan,
with a growth rate of 332.98%, mainly due to the net cash paid by the subsidiary Guoda Drug Store for the
acquisition of Chengda Fangyuan Pharmaceutical Group Co., Ltd. and Shanghai Dingqun Enterprise Management
Consulting Co., Ltd. in the current period, there was no such matter in the same period last year;
40. Net cash flow from investing activities had a year-on-year decrease of 2,250.7388 million yuan, with a growth
rate of -1,497.99%, mainly due to the net cash paid by the subsidiary Guoda Drug Store for the acquisition of
Chengda Fangyuan Pharmaceutical Group Co., Ltd. and Shanghai Dingqun Enterprise Management Consulting
Co., Ltd. in the current period, there was no such matter in the same period last year;
41. Cash proceeds from investments by others had a year-on-year decrease of 44.548 million yuan, with a growth
rate of -100%, mainly due to the receipt of capital increase from minority shareholders in the same period last year.
There was no such matter in this period;
42. Cash received from borrowings had a year-on-year increase of 696.82 million yuan, with a growth rate of
665.54%, mainly due to the receipt of special loan funds for the prevention and control of the COVID-19 outbreak
in this period and the increase in bank loans;
43. Cash receipts related to other financing activities had a year-on-year increase of 317.677 million yuan, with a
growth rate of 16,145.16%, mainly due to the receipt of loans from non-financial institutions in the current period
and the increase in the return of guarantee deposits for the draft received in the current period；
12
44. Sub-total of cash inflows from financing activities had a year-on-year increase of 969.949 million yuan, with a
growth rate of 641.43%, mainly due to the receipt of special loan funds for the prevention and control of the
COVID-19 outbreak in this period, and the receipt of loans from non-financial institutions in this period；
45. Cash repayments for debts had a year-on-year increase of 152.1929 million yuan, with a growth rate of
94.35%, mainly due to the increase in loan repayments during the current period;
46. Cash payments related to other financing activities had a year-on-year increase of 1,056.3758 million yuan,
with a growth rate of 174.70%, mainly due to the repayment of loans from non-financial institutions during the
current period, and the increase in rental payments in retail stores;
47. Sub-total of cash outflows from financing activities had a year-on-year increase of 1,301.6337 million yuan,
with a growth rate of 106.79%, mainly due to the repayment of loans from non-financial institutions in the current
period, and the increase in rent paid by retail stores;
48. Net cash flow from financing activities had a year-on-year decrease of 331.6847 million yuan, with a growth
rate of -31.07%, mainly due to the year-on-year increase in rent paid by retail stores, and the investment funds
paid by the subsidiary Guoda Drug Store for the consolidation of the subsidiary Pudong New Area of Shanghai
Pharmaceutical Medicine Co., Ltd. under the same control in the current period;
49. Effect of foreign exchange rate changes on cash and cash equivalents had a year-on-year increase of 0.1259
million yuan, with a growth rate of 71.52%, mainly due to the impact of exchange rate changes;
50. Net increase in cash and cash equivalents had a year-on-year decrease of 1,657.7437 million yuan, with a
growth rate of -1,040.83%, mainly due to the investment paid by the subsidiary Guoda Drug Store for the
acquisition of Chengda Fangyuan Pharmaceutical Group Co., Ltd. and Shanghai Dingqun Enterprise Management
Consulting Co., Ltd. during the current period. There was no such matter in the same period last year.
II. Progress and influence of the main events as well as solution analysis specification
□ Applicable √ Not applicable
Progress of shares buy-back
□Applicable √Not applicable
Implementation progress of the reduction of repurchases shares by centralized bidding
□Applicable √Not applicable
13
III. Commitments that the company, shareholders, actual controller, offeror, directors,
supervisors, senior management or other related parties have fulfilled during the reporting
period and have not yet fulfilled by the end of reporting period
□ Applicable √ Not applicable
There are no commitments that the company, shareholders, actual controller, offeror, directors, supervisors, senior management or
other related parties have fulfilled during the reporting period and have not yet fulfilled by the end of reporting period.
IV. Financial asset investment
1. Particular about security investment
□ Applicable √ Not applicable
The Company had no security investment in Period.
2. Particulars about derivatives investment
□ Applicable √ Not applicable
The Company had no derivatives investment in Period.
V. Progress of investment projects with raised funds
□ Applicable √ Not applicable
VI. Prediction of 2020 business performance
Estimation on accumulative net profit from the beginning of the year to the end of next report period to be loss probably or the
warning of its material change compared with the corresponding period of the last year and explanation on reason
□ Applicable √ Not applicable
VII. Major contracts for daily operations
□ Applicable √ Not applicable
VIII. Trust financing
□ Applicable √ Not applicable
The Company had no trust financing in Period.
IX. Guarantee outside against the regulation
□Applicable √Not applicable
The Company had no guarantee outside against the regulation in the reporting period.
14
X. Non-operational fund occupation from controlling shareholders and its related party
□ Applicable √ Not applicable
The Company had no non-operational fund occupation from controlling shareholders and its related party.
XI. Registration form for receiving research, communication and interview in the report
period
□Applicable √Not applicable
The Company had no receiving research, communication or interview in the report period.
15
Section IV. Financial Statement
I. Financial statement
1. Consolidate balance sheet
Prepared by China National Accord Medicines Corporation Ltd.
2020-09-30
In RMB
Item 2020-9-30 2019-12-31
Current assets:
Cash and bank balances 6,962,649,007.83 8,885,729,250.47
Settlement provisions
Capital lent
Tradable financial assets
Derivative financial assets
Notes receivable 516,702,799.00 793,301,688.64
Accounts receivable 16,159,274,568.20 10,712,983,544.18
Receivable financing 614,461,184.65 446,342,588.46
Advances to suppliers 528,161,580.38 389,828,785.54
Insurance receivable
Reinsurance receivables
Contract reserve of reinsurance
receivable
Other receivables 625,955,680.32 501,958,841.43
Including: Interest receivable
Dividend receivable 834,914.61
Buying back the sale of financial
assets
Inventories 6,472,039,528.37 5,063,274,143.26
Contractual assets
Assets held for sale
Non-current asset due within one
year
Other current assets 69,483,189.74 102,207,498.20
16
Total current assets 31,948,727,538.49 26,895,626,340.18
Non-current assets:
Loans and payments on behalf
Debt investment
Other debt investment
Long-term account receivable
Long-term equity investment 2,180,792,355.94 2,105,114,410.88
Other equity instruments
116,021,000.00 116,021,000.00
investment
Other non-current financial assets 120,972,350.24 140,000,000.00
Investment properties 129,386,716.54 138,900,358.30
Fixed assets 830,176,528.72 708,000,172.63
Construction in progress 34,002,571.84 31,582,575.84
Productive biological asset
Oil and gas asset
Right-of-use assets 2,364,186,871.11 1,994,757,862.07
Intangible assets 748,672,438.97 374,788,799.48
Expense on Research and
Development
Goodwill 2,746,547,971.28 1,010,057,927.17
Long-term prepaid expenses 422,329,641.93 373,527,968.14
Deferred tax assets 98,512,476.79 63,110,829.12
Other non-current assets 272,872,270.66 77,354,970.39
Total non-current assets 10,064,473,194.02 7,133,216,874.02
Total assets 42,013,200,732.51 34,028,843,214.20
Current liabilities:
Short-term borrowings 3,223,872,627.85 1,453,018,300.01
Loan from central bank
Capital borrowed
Trading financial liability
Derivative financial liability
Notes payable 6,517,277,316.76 5,555,697,557.53
Accounts payable 10,192,012,474.51 6,703,967,826.54
Accounts received in advance
Contract liabilities 319,872,358.57 303,194,940.70
17
Selling financial asset of
repurchase
Absorbing deposit and interbank
deposit
Security trading of agency
Security sales of agency
Employee benefits payable 297,011,161.64 259,640,813.10
Tax payable 266,341,378.00 253,379,524.34
Other payables 1,819,483,384.19 1,822,364,637.62
Including: Interest payable 14,054,694.93 23,632,632.90
Dividend payable 6,389,320.96 6,389,320.96
Commission charge and
commission payable
Reinsurance payable
Liability held for sale
Non-current liabilities due within
722,848,572.29 611,917,847.37
one year
Other current liabilities 888,938.88 749,710.19
Total current liabilities 23,359,608,212.69 16,963,931,157.40
Non-current liabilities:
Insurance contract reserve
Long-term borrowings 31,633,794.44
Bonds payable
Including: Preferred stock
Perpetual capital
securities
Lease liabilities 1,315,854,064.33 1,208,453,029.51
Long-term payable 6,938,189.00 800,000.00
Long-term employee benefits
1,390,000.00 1,433,000.00
payable
Provisions 67,777,417.09
Deferred income 86,200,079.36 88,704,272.88
Deferred tax liabilities 208,604,078.87 118,284,962.77
Other non-current liabilities 536,417,234.89 73,256,514.93
Total non-current liabilities 2,254,814,857.98 1,490,931,780.09
Total liabilities 25,614,423,070.67 18,454,862,937.49
18
Owner’s equity:
Share capital 428,126,983.00 428,126,983.00
Other equity instrument
Including: Preferred stock
Perpetual capital
securities
Capital surplus 4,372,924,761.28 4,470,766,959.44
Less: Inventory shares
Other comprehensive income 46,061,282.19 45,917,342.77
Reasonable reserve
Surplus reserve 214,063,491.50 214,063,491.50
Provision of general risk
Retained earnings 8,492,975,215.79 7,752,265,659.17
Shareholders’ equity attributable to
13,554,151,733.76 12,911,140,435.88
shareholders of the parent
Non-controlling interests 2,844,625,928.08 2,662,839,840.83
Total shareholders’ equity 16,398,777,661.84 15,573,980,276.71
Total liabilities and shareholders’ equity 42,013,200,732.51 34,028,843,214.20
Legal Representative: Lin Zhaoxiong
Accounting Principal: Gu Guolin
Accounting Firm’s Principal: Wang Ying
2. Balance Sheet of Parent Company
In RMB
Item 2020-9-30 2019-12-31
Current assets:
Cash and bank balances 3,623,472,432.84 2,909,417,289.71
Trading financial assets
Derivative financial assets
Notes receivable 14,900,068.42
Accounts receivable 825,123,171.17 571,544,784.65
Receivable financing 14,286,247.98 30,194,682.11
Advances to suppliers 2,255,341.39 7,996,243.28
19
Other receivables 2,238,224,576.05 1,928,941,595.38
Including: Interest receivable
Dividend receivable 834,914.61
Inventories 180,659,951.37 169,422,075.78
Contractual assets
Assets held for sale
Non-current assets maturing within
one year
Other current assets 39,482.38 39,482.38
Total current assets 6,884,061,203.18 5,632,456,221.71
Non-current assets:
Debt investment
Other debt investment
Long-term receivables
Long-term equity investments 7,768,347,868.17 7,698,756,525.83
Investment in other equity
instrument
Other non-current financial assets 120,972,350.24 140,000,000.00
Investment properties 1,460,148.67 1,484,198.56
Fixed assets 14,313,510.88 14,763,656.62
Construction in progress
Productive biological assets
Oil and natural gas assets
Right-of-use assets 5,428,250.46 6,217,504.50
Intangible assets 4,968,294.45 5,838,737.17
Research and development costs
Goodwill
Long-term prepaid expenses 4,688,164.95 6,130,534.55
Deferred tax assets 9,314,310.47 9,327,850.53
Other non-current assets 12,442,236.49 9,000,000.00
Total non-current assets 7,941,935,134.78 7,891,519,007.76
Total assets 14,825,996,337.96 13,523,975,229.47
Current liabilities
Short-term borrowings 247,722,171.73 121,350,644.36
Trading financial liability
20
Derivative financial liability
Notes payable 577,672,670.63 751,577,900.22
Accounts payable 604,053,901.91 322,436,681.01
Accounts received in advance
Contract liabilities 24,386,087.49 7,293,184.46
Employee benefits payable 32,139,686.65 30,469,777.88
Taxes payable 16,082,246.01 22,909,124.90
Other payables 2,505,736,963.13 2,120,794,765.05
Including: Interest payable 358,968.22 861,110.53
Dividend payable
Liability held for sale
Non-current liabilities due within
1,044,745.35 32,640,325.77
one year
Other current liabilities 220,070.94 338,196.81
Total current liabilities 4,009,058,543.84 3,409,810,600.46
Non-current liabilities:
Long-term borrowings 31,633,794.44
Bonds payable
Including: preferred stock
Perpetual capital
securities
Lease liabilities 4,723,839.22 5,461,257.38
Long-term payable 800,000.00 800,000.00
Long-term employee benefits
21,000.00
payable
Accrued liabilities
Deferred income 939,918.30 1,276,698.66
Deferred income tax liabilities
Other non-current liabilities 6,750,487.95
Total non-current liabilities 44,869,039.91 7,537,956.04
Total liabilities 4,053,927,583.75 3,417,348,556.50
Owners’ equity:
Share capital 428,126,983.00 428,126,983.00
Other equity instrument
Including: preferred stock
21
Perpetual capital
securities
Capital surplus 4,468,412,139.15 4,468,385,307.32
Less: Inventory shares
Other comprehensive income 10,573.23 -133,366.19
Special reserve
Surplus reserve 214,063,491.50 214,063,491.50
Retained earnings 5,661,455,567.33 4,996,184,257.34
Total owner’s equity 10,772,068,754.21 10,106,626,672.97
Total liabilities and owner’s equity 14,825,996,337.96 13,523,975,229.47
3. Consolidated Profit Statement (the period)
In RMB
Item Current period Last period
I. Total operating revenue 15,710,564,937.11 13,824,236,956.99
Including: Operating revenue 15,710,564,937.11 13,824,236,956.99
Interest income
Insurance gained
Commission charge and
commission income
II. Total operating costs 15,303,846,841.06 13,468,651,756.73
Including: Operating costs 13,973,474,907.40 12,397,323,704.29
Interest expense
Commission charge and
commission expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal of
insurance contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Tax and surcharges 40,704,486.64 36,849,813.53
Selling expenses 1,021,255,859.95 789,902,994.19
Administrative expense 247,039,895.13 215,510,730.76
22
R&D expense
Finance costs 21,371,691.94 29,064,513.96
Including: Interest cost 69,345,341.35 73,519,643.35
Interest income 47,423,651.34 42,782,208.81
Add: other incomes 10,332,398.22 12,116,753.12
Investment income (Loss is
106,744,145.25 69,951,393.31
listed with “-”)
Including: Investment income
113,954,215.33 86,019,936.49
from associates
Income from the
derecognition of financial assets
-7,260,070.08 -16,118,543.18
measured at amortised cost (Loss is listed
with “-”)
Exchange income (Loss is
listed with “-”)
Net exposure hedging income
(Loss is listed with “-”)
Income from change of fair
value (Loss is listed with “-”)
Credit impairment losses (Loss
-7,503,494.54 -3,211,918.65
is listed with “-”)
Impairment losses (Loss is
-3,838,776.90 -705,879.81
listed with “-”)
Gain on disposal of assets
3,017,582.41 613,909.71
(Loss is listed with “-”)
III. Operating profit (Loss is listed with
515,469,950.49 434,349,457.94
“-”)
Add: Non-operating income 4,558,551.96 3,208,143.43
Less: Non-operating expenses 17,387,648.55 638,789.06
IV. Total profit (Loss is listed with “-”) 502,640,853.90 436,918,812.31
Less: Income taxes 87,693,175.37 80,186,257.89
V. Net profit (Net loss is listed with “-”) 414,947,678.53 356,732,554.42
(i) Classify by business continuity
1. profit or loss from continuing
414,947,678.53 356,732,554.42
operations (net loss listed with ‘-”)
2.termination of net profit (net loss
listed with ‘-”)
(ii) Classify by ownership
23
1. Owners of the parent 354,134,165.83 310,253,592.48
2. Non-controlling interests 60,813,512.70 46,478,961.94
VI. Other comprehensive income, net of
21,752.53
tax
Other comprehensive income
attributable to shareholders of owners of 21,752.53
the parent, net of tax
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1.Changes of the defined
benefit plans that re-measured
2.Other comprehensive
income under equity method that cannot
be transfer to gain/loss
3.Change of fair value of
investment in other equity instrument
4.Fair value change of
enterprise's credit risk
5. Other
(ii) Other comprehensive income
21,752.53
that may be reclassified to profit or loss
1. Other comprehensive
income using the equity method that may 21,752.53
be reclassified to profit or loss
2.Change of fair value of
other debt investment
3.Amount of financial assets
re-classify to other comprehensive
income
4.Credit impairment
provision for other debt investment
5.Cash flow hedging reserve
6.Translation differences
arising on translation of foreign currency
financial statements
7.Other
Net after-tax of other comprehensive
income attributable to minority
24
shareholders
VII. Total comprehensive income 414,969,431.06 356,732,554.42
Total comprehensive income
354,155,918.36 310,253,592.48
attributable to shareholders of the parent
Total comprehensive income
60,813,512.70 46,478,961.94
attributable to non-controlling interests
VIII. Earnings per share:
(i) Basic earnings per share 0.83 0.72
(ii) Diluted earnings per share 0.83 0.72
Enterprise combine under the same control in the Period, the combined party realized net profit of 0.00 Yuan before combination, and
realized -2,559,759.75 Yuan at last period for combined party
Legal Representative: Lin Zhaoxiong
Accounting Principal: Gu Guolin
Accounting Firm’s Principal: Wang Ying
4. Profit Statement of Parent Company (the period)
In RMB
Item Current period Last period
I. Operating revenue 1,045,312,749.83 1,112,624,846.96
Less: Operating cost 998,626,282.80 1,064,701,021.03
Taxes and surcharge 1,971,974.46 1,964,184.59
Sales expenses 16,645,559.49 17,984,619.36
Administration expenses 21,487,255.62 24,299,300.83
R&D expenses
Finance costs -19,457,068.52 -12,688,664.89
Including: Interest cost 12,460,526.51 14,404,910.73
Interest income 32,385,886.23 27,695,670.05
Add: other income 132,260.12 219,828.06
Investment income (Loss is
113,805,608.42 472,311,092.78
listed with “-”)
Including: Investment income
113,923,021.39 91,259,842.03
from associates
Income from the
derecognition of financial assets -117,412.97 -1,201,462.13
measured at amortized cost (Loss is
25
listed with “-”)
Net exposure hedging income
(Loss is listed with “-”)
Changing income of fair
value (Loss is listed with “-”)
Credit impairment losses
-161,522.25
(Loss is listed with “-”)
Impairment loss (Loss is
-477,234.68 -234,019.78
listed with “-”)
Gain on disposal of assets
-165.97 181,433.34
(Loss is listed with “-”)
II. Operating profit (Loss is listed with
139,499,213.87 488,681,198.19
“-”)
Add: Non-operating income 237.88 373.35
Less: Non-operating expense 0.02
III. Total Profit (Loss is listed with “-”) 139,499,451.73 488,681,571.54
Less: Income taxes 6,442,994.33 3,675,740.93
IV. Net profit (Net loss is listed with
133,056,457.40 485,005,830.61
“-”)
(i) profit or loss from continuing
133,056,457.40 485,005,830.61
operations (net loss listed with ‘-”)
(ii) termination of net profit (net
loss listed with ‘-”)
V. Other comprehensive income, net of
21,752.53
tax
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1.Changes of the defined
benefit plans that re-measured
2.Other comprehensive
income under equity method that cannot
be transfer to gain/loss
3.Change of fair value of
investment in other equity instrument
4.Fair value change of
enterprise's credit risk
5. Other
(II) Other comprehensive income 21,752.53
26
that may be reclassified to profit or loss
1. Other comprehensive
income using the equity method that 21,752.53
may be reclassified to profit or loss
2.Change of fair value of
other debt investment
3.Amount of financial
assets re-classify to other
comprehensive income
4.Credit impairment
provision for other debt investment
5.Cash flow hedging
reserve
6.Translation differences
arising on translation of foreign
currency financial statements
7.Other
VI. Total comprehensive income 133,078,209.93 485,005,830.61
VII. Earnings per share:
(i) Basic earnings per share
(ii) Diluted earnings per share
5. Consolidated Profit Statement (form the year-begin to the period-end)
In RMB
Item Current Period Last Period
I. Total operating revenue 42,880,505,125.63 39,423,435,772.29
Including: Operating revenue 42,880,505,125.63 39,423,435,772.29
Interest income
Insurance gained
Commission charge and
commission income
II. Total operating costs 41,581,721,662.96 38,242,360,900.06
Including: Operating costs 37,944,504,626.84 35,110,200,308.48
Interest expense
Commission charge and
commission expense
Cash surrender value
27
Net amount of expense of
compensation
Net amount of withdrawal of
insurance contract reserve
Bonus expense of guarantee slip
Reinsurance expense
Tax and surcharges 110,209,795.96 99,561,207.90
Selling expenses 2,749,994,678.55 2,331,188,042.13
Administrative expenses 690,327,040.05 607,359,068.67
R&D expense
Finance costs 86,685,521.56 94,052,272.88
Including: Interest cost 202,695,852.03 208,314,880.76
Interest income 112,936,201.56 103,423,311.30
Add: other income 46,187,696.54 28,607,672.14
Investment income (Loss is
211,950,494.51 196,824,879.75
listed with “-”)
Including: Investment income
247,559,119.49 255,162,226.48
from associates
Income from the
derecognition of financial assets
-40,767,172.72 -58,387,346.73
measured at amortized cost (Loss is listed
with “-”)
Exchange income (Loss is
listed with “-”)
Net exposure hedging income
(Loss is listed with “-”)
Income from change of fair
value (Loss is listed with “-”)
Credit impairment losses (Loss
-29,083,726.06 -14,646,019.78
is listed with “-”)
Impairment losses (Loss is
-5,582,665.20 -831,434.15
listed with “-”)
Gain on disposal of assets
7,322,907.21 584,184.27
(Loss is listed with “-”)
III. Operating profit (Loss is listed with
1,529,578,169.67 1,391,614,154.46
“-”)
Add: Non-operating income 9,778,532.18 6,881,835.88
Less: Non-operating expense 20,396,541.07 2,388,239.14
28
IV. Total profit (Loss is listed with “-”) 1,518,960,160.78 1,396,107,751.20
Less: Income taxes 297,799,939.72 272,310,616.73
V. Net profit (Net loss is listed with “-”) 1,221,160,221.06 1,123,797,134.47
(i) Classify by business continuity
1. profit or loss from continuing
1,221,160,221.06 1,123,797,134.47
operations (net loss listed with ‘-”)
2.termination of net profit (net loss
listed with ‘-”)
(ii) Classify by ownership
1.Owners of the parent 997,585,746.42 959,408,007.03
2.Non-controlling interests 223,574,474.64 164,389,127.44
VI. Other comprehensive income, net of
143,939.42
tax
Other comprehensive income
attributable to shareholders of owners of 143,939.42
the parent, net of tax
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1.Changes of the defined
benefit plans that re-measured
2.Other comprehensive
income under equity method that cannot
be transfer to gain/loss
3.Change of fair value of
investment in other equity instrument
4.Fair value change of
enterprise's credit risk
5. Other
(ii) Other comprehensive income
143,939.42
that may be reclassified to profit or loss
1. Other comprehensive
income using the equity method that may 143,939.42
be reclassified to profit or loss
2.Change of fair value of
other debt investment
3.Amount of financial assets
re-classify to other comprehensive
29
income
4.Credit impairment
provision for other debt investment
5.Cash flow hedging reserve
6.Translation differences
arising on translation of foreign currency
financial statements
7.Other
Net after-tax of other comprehensive
income attributable to minority
shareholders
VII. Total comprehensive income 1,221,304,160.48 1,123,797,134.47
Total comprehensive income
997,729,685.84 959,408,007.03
attributable to shareholders of the parent
Total comprehensive income
223,574,474.64 164,389,127.44
attributable to non-controlling interests
VIII. Earnings per share:
(i) Basic earnings per share 2.33 2.24
(ii) Diluted earnings per share 2.33 2.24
Enterprise combine under the same control in the Period, the combined party realized net profit of 0.00 Yuan before combination, and
realized -3,587,735.01 Yuan at last period for combined party
Legal Representative: Lin Zhaoxiong
Accounting Principal: Gu Guolin
Accounting Firm’s Principal: Wang Ying
6. Profit Statement of Parent Company (form the year-begin to the period-end)
In RMB
Item Current Period Last Period
I. Operating revenue 2,817,800,113.39 3,120,629,410.26
Less: Operating costs 2,688,190,345.04 2,985,973,415.79
Taxes and surcharge 4,554,615.32 4,483,432.58
Selling expenses 48,021,936.53 49,036,664.17
Administration expenses 64,547,735.37 62,356,107.14
R&D expenses
Finance costs -63,295,185.86 -43,265,784.17
30
Including: interest expenses 34,388,587.85 35,792,756.82
Interest income 98,955,206.08 80,175,392.47
Add: other income 762,181.59 552,592.19
Investment income (Loss is
863,439,369.20 1,078,420,637.97
listed with “-”)
Including: Investment income
247,472,516.77 272,540,375.14
from associates
Income from the
derecognition of financial assets
-1,644,381.22 -3,380,337.41
measured at amortised cost (Loss is
listed with “-”)
Net exposure hedging income
(Loss is listed with “-”)
Changing income of fair
value (Loss is listed with “-”)
Credit impairment losses
-976,022.96 -2,527,287.33
(Loss is listed with “-”)
Impairment loss (Loss is
-719,966.55 -336,132.62
listed with “-”)
Gain on disposal of assets
-165.97 155,358.82
(Loss is listed with “-”)
II. Operating profit (Loss is listed with
938,286,062.30 1,138,310,743.78
“-”)
Add: Non-operating income 1,834.65 46,442.75
Less: Non-operating expense 52,122.74
III. Total Profit (Loss is listed with “-”) 938,235,774.21 1,138,357,186.53
Less: Income taxes 16,088,274.42 12,674,965.45
IV. Net profit (Net loss is listed with
922,147,499.79 1,125,682,221.08
“-”)
(i) profit or loss from continuing
922,147,499.79 1,125,682,221.08
operations (net loss listed with ‘-”)
(ii) termination of net profit (net
loss listed with ‘-”)
V. Other comprehensive income, net of
143,939.42
tax
(I) Other comprehensive income
items which will not be reclassified
subsequently to profit of loss
1.Changes of the defined
31
benefit plans that re-measured
2.Other comprehensive
income under equity method that cannot
be transfer to gain/loss
3.Change of fair value of
investment in other equity instrument
4.Fair value change of
enterprise's credit risk
5. Other
(II) Other comprehensive income
143,939.42
that may be reclassified to profit or loss
1. Other comprehensive
income using the equity method that 143,939.42
may be reclassified to profit or loss
2.Change of fair value of
other debt investment
3.Amount of financial
assets re-classify to other
comprehensive income
4.Credit impairment
provision for other debt investment
5.Cash flow hedging
reserve
6.Translation differences
arising on translation of foreign
currency financial statements
7.Other
VI. Total comprehensive income 922,291,439.21 1,125,682,221.08
VII. Earnings per share:
(i) Basic earnings per share
(ii) Diluted earnings per share
7. Consolidated Cash Flow Statement (form the year-begin to the period-end)
In RMB
Item Current Period Last Period
I. Cash flows arising from operating
activities:
Cash received from sales of good 42,418,077,097.10 40,055,008,686.20
32
or rendering of services
Net increase of customer deposit
and interbank deposit
Net increase of loan from central
bank
Net increase of capital borrowed
from other financial institution
Cash received from original
insurance contract fee
Net cash received from reinsurance
business
Net increase of insured savings
and investment
Cash received from interest,
commission charge and commission
Net increase of capital borrowed
Net increase of returned business
capital
Net cash received by agents in sale
and purchase of securities
Receipts of taxes and surcharges
10,784,614.07 3,508,074.72
refunds
Other cash receipts relating to
1,216,248,037.55 517,348,861.84
operating activities
Sub-total of cash inflows from
43,645,109,748.72 40,575,865,622.76
operating activities
Cash paid for goods and services 37,533,521,802.87 36,077,610,134.36
Net increase of customer loans and
advances
Net increase of deposits in central
bank and interbank
Cash paid for original insurance
contract compensation
Net increase of capital lent
Cash paid for interest, commission
charge and commission
Cash paid for bonus of guarantee
slip
Cash paid to and on behalf of
1,913,705,773.98 1,672,811,261.76
employees
Cash paid for all types of taxes 1,148,433,266.37 959,672,684.15
Cash payments related to other
1,066,101,719.26 806,978,262.18
operating activities
33
Sub-total of cash outflows from
41,661,762,562.48 39,517,072,342.45
operating activities
Net cash flows from operating activities 1,983,347,186.24 1,058,793,280.31
II. Cash flows arising from investing
activities:
Cash receipts from returns of inves
19,027,649.76
tments
Cash receipts from returns on inve
159,574,046.42 78,242,963.78
stments
Net cash received from disposal of
fixed assets, intangible assets and other 5,274,705.47 4,977,626.76
long-term assets
Net cash received from disposal of
subsidiaries and other units
Cash receipts related to other
22,040,000.00 368,614,498.90
investing activities
Subtotal of cash inflow from investing
205,916,401.65 451,835,089.44
activities
Cash paid for acquisition of fixed
assets, intangible assets and other 188,880,164.05 166,514,970.91
long-term assets
Cash paid for acquisition of
28,410,468.41 84,539,317.61
investments
Net increase of mortgaged loans
Net cash paid for acquisition of
2,384,615,064.76 5,328,000.00
subsidiaries and other business units
Cash payments related to other
5,000,000.00 345,703,306.28
investing activities
Subtotal of cash outflow from investing
2,606,905,697.22 602,085,594.80
activities
Net cash flows from investing activities -2,400,989,295.57 -150,250,505.36
III. Cash flows arising from financing
activities
Cash proceeds from investments
44,548,000.00
by others
Incl: Cash proceeds from
subsidiary investments by 44,548,000.00
non-controlling shareholders
Cash received from borrowings 801,520,037.57 104,700,000.00
Cash receipts related to other
319,644,627.50 1,967,629.61
financing activities
Sub-total of cash inflows from
1,121,164,665.07 151,215,629.61
financing activities
34
Cash repayments for debts 313,500,000.00 161,307,142.79
Cash payments for distribution of
dividends or profit and interest 545,931,923.60 452,866,856.35
expenses
Incl: Profit and dividends paid to
non-controlling shareholders of 62,338,791.80 28,493,123.11
subsidiaries
Cash payments related to other
1,661,056,163.63 604,680,365.03
financing activities
Subtotal of cash outflow from financing
2,520,488,087.23 1,218,854,364.17
activities
Net cash flows from financing activities -1,399,323,422.16 -1,067,638,734.56
IV. Effect of foreign exchange rate
-50,126.70 -175,994.42
changes on cash and cash equivalents
V. Net increase of cash and cash
-1,817,015,658.19 -159,271,954.03
equivalents
Add: Cash and cash equivalents at
8,426,071,170.16 7,634,936,037.30
beginning of the year
VI. Cash and cash equivalents at end of
6,609,055,511.97 7,475,664,083.27
year
8. Cash Flow Statement of Parent Company (form the year-begin to the period-end)
In RMB
Item Current period Last period
I. Cash flows arising from operating
activities:
Cash received from sales of good
2,801,262,096.63 3,217,890,947.38
or rendering of services
Write-back of tax received
Other cash receipts relating to
118,590,737.66 32,674,054.58
operating activities
Sub-total of cash inflows from
2,919,852,834.29 3,250,565,001.96
operating activities
Cash paid for goods and services 2,670,157,831.18 3,191,926,190.64
Cash paid to and on behalf of
77,688,934.66 73,601,798.69
employees
Cash paid for all types of taxes 61,976,566.00 43,156,828.71
Cash payments related to other
39,479,023.87 24,724,274.57
operating activities
Sub-total of cash outflows from
2,849,302,355.71 3,333,409,092.61
operating activities
35
Net cash flows from operating activities 70,550,478.58 -82,844,090.65
II. Cash flows arising from investing
activities:
Cash receipts from returns of inves
32,664,096.76
tments
Cash receipts from returns on inve
333,064,697.85 619,976,538.54
stments
Net cash received from disposal of
fixed assets, intangible assets and other 2,900.00 3,961,383.00
long-term assets
Net cash received from disposal of
subsidiaries and other units
Cash receipts related to other
1,996,202,038.52 1,482,390,000.00
investing activities
Sub-total of cash inflow from investing
2,361,933,733.13 2,106,327,921.54
activities
Cash paid for acquisition of fixed
assets, intangible assets and other 11,926,875.85 6,777,035.03
long-term assets
Cash paid for acquisition of
19,998,000.00
investments
Net cash received from
subsidiaries and other units obtained
Cash payments related to other
2,296,122,707.02 1,812,850,181.28
investing activities
Sub-total of cash outflows from
2,308,049,582.87 1,839,625,216.31
investing activities
Net cash flows from investing activities 53,884,150.26 266,702,705.23
III. Cash flows arising from financing
activities
Cash received from absorbing
investment
Cash received from borrowings 63,864,821.52 10,000,000.00
Cash receipts related to other
24,518,926,964.22 18,437,509,464.22
financing activities
Sub-total of cash inflow from financing
24,582,791,785.74 18,447,509,464.22
activities
Cash repayments for debts 43,700,000.00 10,000,000.00
Cash payments for distribution of
285,557,151.27 191,576,803.94
dividends, profit or interest expenses
Cash payments related to other
23,660,780,660.15 17,703,057,206.85
financing activities
36
Sub-total of cash outflow from
23,990,037,811.42 17,904,634,010.79
financing activities
Net cash flows from financing activities 592,753,974.32 542,875,453.43
IV. Effect of foreign exchange rate
-50,126.70 -175,994.42
changes on cash and cash equivalents
V. Net increase of cash and cash
717,138,476.46 726,558,073.59
equivalents
Add: Cash and cash equivalents at
2,894,333,956.38 1,817,654,598.01
beginning of the year
VI. Cash and cash equivalents at end of
3,611,472,432.84 2,544,212,671.60
year
II. Explanation on financial statement adjustment
1. Financial statement adjustment at the beginning of the first year when implementation of new revenue
rules and new leasing rules from 2020
□Applicable √Not applicable
2. Retrospective adjustment of the comparative data for initial implementation of new revenue rules and
new leasing rules from 2020
□Applicable √Not applicable
III. Audit report
Whether the 3rd quarterly report has been audited or not
□Yes √ No
3Q report of the Company is unaudited.
China National Accord Medicines Corporation Ltd.
Legal representative: Lin Zhaoxiong
October 22, 2020
37
